JAKAVI, known generically as ruxolitinib, is a medication primarily used in the treatment of certain blood disorders, including myelofibrosis, polycythemia vera, and acute graft-versus-host disease in patients who have undergone bone marrow transplantation. It operates as a Janus kinase (JAK) inhibitor, specifically targeting JAK1 and JAK2 enzymes. These enzymes play a crucial role in the signaling pathways that regulate blood cell production within the bone marrow. By inhibiting their activity, JAKAVI can help manage the overproduction of blood cells, alleviate symptoms associated with these disorders, and improve quality of life for patients. It is typically administered in tablet form and requires a prescription. Like all medications, it may have side effects, and its use should be closely monitored by a healthcare provider.